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Volume 53, Number 17S Abstracts 63Scant differences existed in discharge ambulation (WI 91.6%
vs 91.9%, p0.879), 1-year amputation (WI 12.3% vs
8.9%, p0.226), or 1-year primary patency (WI 64.4% vs
70.8%, p0.297). On multivariate analysis, predictors of
WI in IC included COPD (OR 2.24, 95% CI 1.08-4.62)
and age55 (OR 2.6, 95% CI 1.22-5.55). In CLI, predic-
tors included tibial versus popliteal target (OR 1.64, 95%CI
1.09-2.45) and age55 (OR 1.74, 95% CI 1.0-3.04).
Conclusions: In this large contemporary cohort of
patients undergoing LEB, WI rates were low and did not
have significant long-term implications. While hospital re-
source utilization secondary to prolonged LOS was in-
creased, outcomes related to function, graft patency, and
limb salvage were not affected. WI is a self-limiting compli-
cation and should not significantly impact the decision of
whether or not to perform a LEB.
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Artery Stents: Beyond TASC II
Rachel C. Danczyk1, Erica L. Mitchell1, Sharon G. Kry-
ger1, Chad Burk1, Sarguni Singh1, Timothy K. Liem1,
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Objectives: Endovascular stents are accepted therapy
for TASC A, B and some C lesions. Surgery is the
recommended therapy for patients with TASC D lesions
including those with both ipsilateral common iliac (CIA)
and external iliac artery (EIA) stenoses/occlusion. This
study compares anatomic patency and operative salvage
rates for combined ipsilateral CIA and EIA stenting
(TASC D) versus CIA or EIA stents alone (TASC A, B
or C).
Methods: All patients (n481) who underwent iliac
artery stenting at a single institution between 1998 and
2010 were identified. Patient comorbidities and outcomes
were retrospectively reviewed and analyses were performed
using multivariate regression and Kaplan-Meier curves.
Results: There were 325 extremities with CIA stents,
173 with EIA stents, and 137 with both CIA and EIA
stents. There was no significant difference in demographics,
comorbidities, or treatment indications between groups.
During follow-up, 160 patients died, 83 underwent endo-
vascular reintervention, and 34 required salvage operation.
Mean times to follow-up, death, reintervention, and oper- ctive salvage were 2.50.1, 5.50.3, 7.00.6, and
.80.5 years, respectively. CIA and EIA stenting in com-
ination was not a predictor of death, reintervention, or
alvage operation. Survival, reintervention-free survival,
nd salvage operation-free survival were similar between
hose who hadCIA or EIA stents alone and those with both
IA and EIA stents (all p0.05).
Conclusions: CIA stents, EIA stents, and the combi-
ation of ipsilateral CIA and EIA stents have similar out-
omes. Salvage operations for iliac artery stent failure are
ncommon and not influenced by the location or extent of
liac artery stent placement. This study suggests that a more
ggressive approach with total endovascular management
or some TASCD lesion is acceptable. TASC II recommen-
ations for endovascular therapy for aorto-iliac disease
hould be extended to consider selected patients with ipsi-
ateral CIA and EIA stenoses/occlusion.
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ascular
emoropopliteal Intervention
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Objectives: The use of antiplatelet agents to improve
esults of peripheral angioplasty and stenting is not well
efined. The purpose of this study was to analyze the
ontemporary use of antithrombotic therapy and the
ffect on outcome after endovascular femoropopliteal
nterventions.
Methods: All primary endovascular interventions in
he femoropopliteal arteries between 2006 and 2008
ere identified from the National Vascular Registry
Swedvasc). The cohort was cross-linked with the Na-
ional Pharmaceutical Registry providing information
bout post-procedure antithrombotic treatment. Demo-
raphics, major amputation and death were analyzed
sing logistic regression models and Kaplan-Meier sur-
ival analysis.
Results: 3281 patients underwent endovascular inter-
ention in the femoropopliteal segment (balloon angio-
lasty (PTA) 68%; stent/stentgraft 18%; subintimal angio-
lasty (SAP) 14%). Post-procedure antithrombotic therapy
as: ASA (acetylsalicylic acid) 43%, clopidogrel 5%, ASA-
lopidogrel 24%, warfarin 4%, or other 24%. Dominating
